Hormone replacement therapy and cardiovascular disease.
Coronary heart disease is the principal cause of death in postmenopausal women. Postmenopausal women have an elevated cardiovascular risk profile in the form of android obesity (increased waist/hip ratio), hyperinsulinemia, impaired glucose tolerance, increased insulin resistance and elevated plasma LDL, VLDL, serum triglyceride and lipoprotein (a). A significant decrease in the relative risk of cardiovascular disease is observed with estrogen replacement therapy. The addition of progestogens commonly used in hormone replacement regimes does not, based on present evidence, seem to affect cardiovascular protection adversely. The literature on this subject has been reviewed and recommendations made with implications for the future.